Mr. Aras Azadian reports

AVICANNA ANNOUNCES RESULTS OF ANNUAL GENERAL AND SPECIAL MEETING

All of management's nominees listed in Avicanna Inc.'s management information circular dated April 2, 2026, were elected as directors of the company at its annual general and special meeting of shareholders held May 7, 2026.

Detailed results of the vote for the election of directors held at the meeting are set out in the attached table.

At the meeting, the company's shareholders also approved: (i) fixing the number of directors for the ensuing year at five and empowering the board of directors of the company to adjust such number between shareholder meetings by way of resolution in accordance with the company's constating documents; (ii) the reappointment of Ramirez Jimenez International CPAs, as the company's auditor for the ensuing year and authorized the board of directors to fix the auditor's remuneration; and (iii) the unallocated awards and ratification awards under the company's omnibus long-term incentive plan, the full text of which was set forth in the circular.

About Avicanna Inc.

Avicanna is an international biopharmaceutical company specializing in the commercialization of proprietary and evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has established scientific and medical affairs platforms that support its four commercial stage business pillars and have resulted in the commercialization of more than 50 finished products.

• Medical Cannabis formulary (RHO Phyto): The formulary offers a diverse range of proprietary products including oral, sublingual, topical and transdermal deliveries with varying ratios of cannabinoids, supported by continuing patient and medical community education. RHO Phyto is an established brand in Canada currently available nationwide across several channels and expanding into new international markets.
• Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients' needs and enhance the medical cannabis patients' journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens.
• Pharmaceutical pipeline: Leveraging Avicanna's scientific platform, vertical integration and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain and various neurological disorders.
• Active pharmaceutical ingredients (Aureus Santa Marta): Active pharmaceutical ingredients supplied by the company's majority owned subsidiary, Santa Marta Golden Hemp SAS (SMGH), is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the company's international partners for use in the development and production of food, cosmetics, medical and pharmaceutical products. SMGH also forms part of the company's supply chain, and is a source of reliable input products for its consumer retail, medical cannabis and pharmaceutical products globally.

We seek Safe Harbor.